Introduction
Chronic myeloid leukemia (CML) is a clonal disorder of the hematopoietic system with the Philadelphia (Ph 1 ) chromosome, a special cytogenetic hallmark resulting from the translocation of abl on chromosome 9 to bcr on chromosome 22. The bcr/abl fusion is present in over 95% patients with CML. It can generate a chimeric oncoprotein whose expression in hematopoietic cells induces resistance to apoptosis, growth factor independence, alterations in cell-cell and cell-matrix interactions, and leukemogenesis. [1] [2] [3] [4] Recent studies show that CML, like most solid tumors, is driven by tumor-induced angiogenesis. 5, 6 Leukemia cells expressing bcr/abl secrete several angiogenic factors including VEGF, which regulates hematopoietic cell survival by an internal autocrine loop mechanism. 7 In CML, VEGF levels are elevated in both the plasma of patients and the conditioned media taken from CML cells. 8 The abnormal VEGF expression in CML has been suggested to be driven largely by bcr/abl, especially at the chronic phase of the disease where bcr/abl appears to be the sole oncogenic event. 9 Thus, targeting both VEGF and bcr/abl may represent novel therapy strategy for CML.
We have previously reported an anti-VEGF antisense strategy, which significantly reduces VEGF expression in leukemia cells and suppresses not only the growth of leukemic tumors but also tumor angiogenesis. 10 In addition, Imatinib mesylate (STI-571), a tyrosine kinase inhibitor against bcr/abl, and other specific kinase targets have also been reported to reduce VEGF secretion in leukemia cells. 11 The present study was therefore designed to determine if the combination of bcr3/abl2 and VEGF antisense oligodeoxyribonucleotides (AS-ODNs) increases the susceptibility of CML cells to apoptosis-inducing stimuli in vitro and decrease in vivo growth of leukemia tumors, in an attempt to develop a novel and more effective therapy strategy for leukemia.
Materials and methods

Cell culture and reagents
The K562 cells derived from the leukemia cells of a CML patient in blastic crisis were maintained in RPMI-1640 with 10% fetal bovine serum containing 100 U/ml penicillin and 100 mg/ml streptomycin (Gibco BRL) in a humidified incubator at 371C with 5% CO 2 .
STI571 was kindly provided by Novartis (Basel, Switzerland) and prepared as a 10 mmol/l stock solution in sterile DMSO (Sigma, St Louis, MO, USA) at À201C. Working concentrations were prepared in medium just before each experiment. Etoposide (Sigma Dublin, Ireland) was formulated in sterile DMSO before use.
Oligodeoxyribonucleotides
Phosphorothioate ODNs ([S]ODNs) were synthesized on a Lynx-made DNA synthesizer (Lynx Therapeutics, Hayward, CA, USA) by means of b-cyanoethilphosphoramidite chemistry. The antisense sequences directed against the bcr exon 3/abl exon 2 breakpoint and the exon 3 of VEGF, respectively, were designed as described previously: 12, 13 antisense B3A2
0 . The nonsense sequence used was a randomization of the antisense sequence to assess the ODNs' effect on K562 cells: N-ODN ¼ 5 0 -CATTTCTTGCTCTCCACG-3 0 . K562 cells were either transfected with ASO-B3A2 or ASO-VEGF or both of them or N-ODNs using Oligofectaminet Reagent (Life Technologies, Carlsbad, CA, USA), meanwhile transfected without ODNs as control. According to the manufacturer's protocol, we selected the 200 nM AS-ODNs concentrations to obtain the highest transfective efficiency. During transfection of the combined ODNs, each ODN concentration should be 100 nM to assure much ODNs to be taken by Oligofectaminet Reagent and may allow us easily to observe a significant and additive antiproliferative and proapoptotic effects on K562 cells.
RT-PCR analysis
Total RNA was extracted from 1 Â 10 6 cells using mini-DNAfree total RNA extraction kit (Waston Shanghai) following the manufacturer's instructions. Complementary DNA (cDNA) was subsequently synthesized from total RNA using SUPERSCRIPT I RNaseH Reverse Transcriptase (Life Technologies). Different aliquots of cDNA were amplified with specific primers for bcr3/abl2 and VEGF. The b 2 -MG and GAPDH were used as control for successful cDNA synthesis and semiquantitative analysis, respectively. PCR was performed under standard condition with 35 cycles of 45 s at 941C, 1 min at 601C and 1 min at 721C. The PCR products were visualized by electrophoresis in a 1% agarose gel containing 0.5 mg/ml of ethidium bromide. Densities of the amplified bcr3/abl2, VEGF, b 2 -MG and GAPDH were analyzed using the Kodak digital imaging system (Eastman Kodak Company, Rochester, NY, USA). Results were expressed as a ratio of quantified bcr3/abl2 product over GAPDH product or VEGF product over b 2 -MG product.
Measurement of cell growth and viability
K562 cells were plated into 96-well plates at a concentration of 3 Â 10 4 cells/well and were treated by different AS-ODNs as described above. After 24 h, the cells were washed and cultured for an additional 24 h without serum or with STI571 (0.1 mM). For measurement of survival, the MTT assays were performed as described previously (measured at 570 nm). 10 Cell proliferation assays were also performed. At 72 h, cells were harvested, and viable cells were counted using homocytometer and Trypan blue dye exclusion on triplicate samples.
Programmed cell death assays
The Annexin V fluorescent assay was performed as described previously.
10 K562 cells were treated with different types of AS-ODNs to inhibit the activities of bcr3/abl2 or VEGF or both. After 24 h, cells were incubated with cytotoxic drug etoposide (5 mM VP16), STI571 (0.1 mM) and serum deprivation, and were analyzed for cell apoptosis by the fluorescent Annexin V method at 24 h.
Animal studies
Female nu/nu nude mice (6-8 weeks old) of BALB/C background were obtained under strict pathogen-free conditions, receiving sterilized pellets and water ad libitum. K562 cells (a single-cell suspension of 1.5 Â 10 7 in 200 ml of serum-free RPMI-1640) were injected subcutaneously into the right flank of the mice. Approximately 2 weeks later, most tumors had grown in vivo to approximately 0.50 cm 3 . The mice were then randomized into treatment and control groups with near-equivalent distributions by weight and tumor size. In vivo, we selected the same transfection conditions used in vitro and obtained the 1.0 mM ODN concentration at which concentration Oligofectaminet Reagent will take the most amount of ODNs with the highest transfection efficiency. According to the method reported previously, 14 we selected the serum-free medium as control group without significant influence for the evaluation of in vivo experiments' results. For the first experiment ( Figure 3A ), the administration of drugs or serum-free medium began the day on which the animals were assigned to groups (day 1). The intratumoral treatment with 100 ml of serum-free medium, 100 ml of 1.0 mM ASO-B3/A2, or 100 ml of 1.0 mM ASO-VEGF or 100 ml of 0.5 mM bcr3/abl2 þ 0.5 mM VEGF AS-ODNs was started and repeated every 3 days for four times. In the second experiment ( Figure 3A ), the mice were treated with STI571 daily oral gavages of 70 mg/kg from days 1 to 10, in combination with different AS-ODNs treatments (as described in the first experiment). STI571 (Gleevec, Novartis) stored at room temperature and diluted in 150 ml of sterile distilled H 2 O at the time of use. All control groups received daily administration of water by oral gavages. The tumors were measured twice weekly with calipers, and tumor volumes were calculated by the formula (p/6 (W 1 Â W 2 Â W 2 )), where W 1 represents the largest tumor diameter and W 2 represents the smallest tumor diameter. At the end of the measurement period, the mice were killed and their tumors were excised. Metastases at distant sites were not found. Xenograft studies were approved by the National Cancer Institute's Animal Care and Use Committee, and all animal care was in accordance with institutional guidelines.
Histology
The tumors were excised, fixed in 10% (vol/vol) neutral-buffered formalin overnight at 41C, paraffin embedded, serially sectioned through the entire tumor for examination of tumor vessel density, cell morphology and apoptosis. Staining of tumor tissue vessels was performed as described previously. 12 The relative number of vascular endothelial cells/tumor section was calculated by counting the number of vessels at Â 200 magnification with a square grid equaled to a field size of 0.43 mm 2 . Calculations were performed on five fields, selected at random/section from three mice in each group. Terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) staining was performed on paraffin-embedded sections of tumor using an in situ cell death detection kit (Roche Molecular Biochemicals, Germany). Sections were digested for 15 min at room temperature with proteinase K (20 mg/ml), permeabilized with 0.1% sodium citrate buffer containing 0.1% Triton X-100 for 2 min at 41C and incubated with the TUNEL labeling mix at 371C for 1 h.
Statistical analysis
All experiments were performed in triplicate or quadruplicate. The results were expressed as the mean7s.d. The paired Student's test was used to determine the statistical significance of the data obtained. Analyses were computed using the statistical software SPSS version 11.0. A P-value of o0.05 was taken to represent a statistically significant difference between group means.
Results
Bcr3/abl2 and VEGF antisense ODNs downregulate bcr3/abl2 and VEGF mRNA expression Bcr3/abl2 and VEGF antisense ODNs inhibit K562 cell growth
As seen in Table 1 , 72 h after transfection, the inhibition of K562 cell proliferation induced by 200 nM bcr3/abl2 or VEGF AS-ODNs was 13.47 or 12.79%, respectively. However, the combination of low concentrations of bar3/abl2 with VEGF AS-ODNs (100 nM each) inhibited cell proliferation by 41.55% (P ¼ 0.0084 vs control). The unspecific growth-inhibitory effect of the nonsense control ODNs was comparatively low (1.14%). 
SPOTLIGHT
Combination of bcr3/abl2 and VEGF antisense ODNs enhances the sensibility of K562 cells to apoptosis-inducing stimuli STI571 is a tyrosine kinase inhibitor and is active against bcr/abl and other specific kinase targets. K562 cells are shown to be highly sensitive to STI571-induced apoptosis. STI571 at concentrations varying from 0.01 to 100 mM were used to determine if the effect of STI571 on K562 cells is concentration dependent. The results obtained were analyzed by the median effect method to calculate the doses with 50% inhibition of proliferation (IC 50 values) and the IC 50 was found to be at a concentration of 0.2 mM, as described previously. 15 In (Figure 2b ), a significant growth inhibition was observed in the cells treated with bcr3/ abl2 and VEGF combined AS-ODNs. As seen in the Figure 2a We further studied the effects of bcr3/abl2 and VEGF AS-ODNs on K562 cell apoptosis. K562 cells were incubated for 24 h after transfection with 200 nM ASO-B3/A2, 200 nM ASO-VEGF, or 100 nM bcr3/abl2 þ 100 nM VEGF AS-ODNs, or 200 nM nonsense ODNs, followed by washing and then incubation for an additional 24 h either with serum ( Figure 2c 4271.28% (with etoposide group), respectively. A significant induction of programmed cell death was, however, observed after the transfection with both bcr3/abl2 (100 nM) and VEGF AS-ODNs (100 nM). The percentages of Annexin V-positive cells were 15.5674.47% (without serum group) and 11.9172.64% (with etoposide group), respectively (P without serum ¼ 0.0387, P with etoposide ¼ 0.0427, vs serum group). 
The exposure of cells for 24 h to 0.1 mM STI571 negligibly induced apoptosis. However, when cells exposed to different AS-ODNs in combination with 0.1 mM STI571, a clear increase in apoptosis was observed. The percentages of Annexin V-positive cells were 10.5170.93% in the group with STI571 þ ASO-B3/A2, 11.4571.59% in the group with STI571 þ ASO-VEGF, 20.2173.40% in the group with STI571 þ both ASO-B3/ A2 and ASO-VEGF, respectively. There was a statistically significant difference between the groups of STI571 þ ASOB3/ A2 þ ASO-VEGF and STI571 (P ¼ 0.002156), the groups of STI571 þ ASO-B3/A2 þ ASO-VEGF and STI571 þ ASO-B3/A2 (P ¼ 0.0057), and the groups of STI571 þ ASO-B3/A2 þ ASO-VEGF and STI571 þ ASO-VEGF (P ¼ 0.01164).
Effects of different antisense ODNs on tumor growth in vivo
In the first experiment ( Figure 3B ), the mice were randomized into treatment and control groups. An intratumoral administration with serum-free medium or 1.0 mM of either bcr3/abl2 or VEGF AS-ODNs, or 0.5 mM bcr3/abl2 þ 0.5 mM VEGF AS-ODNs (10-12 mice/group) was started and repeated every 3 days for a total of four times. At the end of treatment, tumor sizes were measured. The mean tumor size was 5025.937870.12 mm 3 in serum-free medium group, 3861.0871849.27 mm 3 in the ASO-B3/A2 group and 4157.5371910.42 mm 3 in the ASO-VEGF group. In contrast, tumor size in the ASO-B3/A2 and ASO-VEGF combined group was 2119.2871225.77 mm 3 . The difference of tumor sizes between the control and different treatment groups was significant (P ASO-B3/A2 ¼ 0.0297, P ASO-VEGF ¼ 0.0469, P ASO-B3/A2 þ VEGF ¼ 0.0040 vs control; P ASO-B3/A2 þ VEGF ¼ 0.0328 vs ASO-B3/A2 group; P ASO-B3/A2 þ VEGF ¼ 0.0319 vs ASO-VEGF group). As compared with the control group, the decreased percentage of tumor size was 23.18, 17.28 and 57.83% after treatment, respectively. In the second experiment ( Figure 3C ), the in vivo tumor growth inhibition induced by STI571 alone or in combination with different AS-ODNs was studied. After fourtime intratumoral injections of AS-ONDs in combination with STI571 daily oral gavages of 70 mg/kg from days 1 to 10, the mean tumor size was 5702.137766.70 mm 3 in serum-free medium group, 4713.2671132.21 mm 3 in the STI571 group, 3098.1771112.59 mm 3 in the STI571 þ ASO-B3/A2 group, 3015.8871100.40 mm 3 in the STI571 þ ASO-VEGF group and 1216.227397.11 mm 3 in the STI571 þ the combination of bcr3/ abl2 and VEGF AS-ODNs. A marked but not significant difference of tumor growth inhibition was observed in the group treated with STI571 and bcr3/abl2 AS-ODNs (P ¼ 0.01072 vs control), or in the group treated with STI571 and VEGF AS-ODNs (P ¼ 0.00569 vs control). In contrast, a significant difference was observed in the group treated with STI571 þ the combination of bcr3/abl2 and VEGF AS-ODNs (P ¼ 0.002358 vs control; P ¼ 0.04645 vs STI571 þ ASO-B3/A2 group; P ¼ 0.04734 vs STI571 þ ASO-VEGF group). No obvious adverse effect of this inoculation on the animals' behavior was noted during experimental periods. Figure 3 (A) The protocol used in the first and second experiments. (B and C) The growth rate of subcutaneous tumors in nude mice. In (B), treatment consisted of serum-free medium or either 1 mM ASO-B3/A2(100 ml) or 1 mM ASO-VEGF (100 ml) or 0.5 mM bcr3/ abl2 þ 0.5 mM VEGF AS-ODNs (100 ml). In (C), adding 70 mg/kg STI571 to each group from days 1 to 10. Intratumoral injections were given every 3 days for a total of four times. (D and E) Microphotographs of xenograft sections. a1, a2: Serum-free medium group; b1, b2: ASO-B3/ A2 group; c1, c2: ASO-VEGF group; d1, d2: the combined therapy group. 
SPOTLIGHT
Histopathological analysis
Under the light microscope, H&E staining of formalin-fixed, paraffin-embedded section of the tumor groups revealed that in control group, leukemia cells were large and had high nuclear to cytoplasmic ratio with abundant cytoplasm and prominent nucleoli ( Figure 3D:a1) . Apoptotic cells were characterized by pyknotic nuclei and cytoplasmic blebbing. The nuclei of these cells were strongly stained for TUNEL reactivity, as expected for cells undergoing apoptosis ( Figure 3D:a2) . In both singleagent groups, there was still a net tumor growth ( Figure 3D:b1,b2,c1,c2) , despite an evident increase in cell apoptosis. In contrast, histological analysis revealed an apparent reduction of both cell viability and tumor architecture in the combined therapy group (Figure 3D:d1) , accompanied by an increase in tumor cell apoptosis ( Figure 3D:d2) .
Tumor microvessel analysis
A marked decrease in the numbers of endothelial cells and vessel structures was observed in the combined groups of ASO-B3/A2 and ASO-VEGF ( Figure 3E, 6 .3770.57/field), compared with those in the groups of ASO-B3/A2 ( Figure 3E, 14 .6871.69/ field), ASO-VEGF group ( Figure 3E, 16 .1273.15/field) and control ( Figure 3E , 26.7275.04/field). The combined therapy group achieved the strongest inhibiting effect (P ¼ 0.00104 vs control; P ¼ 0.0005 vs ASO-B3/A2 group; P ¼ 0.0019 vs ASO-VEGF group).
Discussion
CML is ideally suited for experimental therapeutic approaches with AS-ODNs because the Ph 1 chromosome translocation results in leukemia-specific transcript. A number of studies have shown that bcr/abl antisense ODNs have antileukemia effects in vitro and in vivo in mice. 16 More recently, increased vascularity and plasma VEGF level were found in patients with CML, where both autocrine and paracrine VEGF/VEGF-R systems coexist. Our previous study has also shown that the antisense-VEGF ODNs can effectively inhibit K562 xenografted tumor growth in nude mice. 10 In addition, being not influenced by tumor cell cycles, the antiangiogenic therapy could be an excellent supplement to other therapeutic strategies. Therefore, combination of ASO-B3/A2 with ASO-VEGF appears to be rational and promising for future clinical use.
Recently, the treatment of CML has been revolutionized by the introduction of STI571, which has been demonstrated to exert remarkable clinical efficacy in CML. It has also been found that long-term use of STI571 may result in a reduced efficacy, cell resistance and disease progression. Clinical trials with STI571 have shown that blast-crisis patients frequently progress within 3-6 months of treatment, suggesting that bcr/abl inhibition is not sufficient to prevent disease progress or to restrict clonal expansion of resistant cells. 17 Several mechanisms of STI57 resistance have been suggested, including point mutations within the abl kinase domain, 18 gene amplification of the bcr/abl locus and bcr/abl mRNA overexpression, 19 all leading to reactivation of bcr/abl kinase. It has also been shown that STI57 resistance can be induced in vitro by elevating bcr/abl protein level in an expression model. 20 One possible approach to this problem involves the combination of STI571 with other antileukemic compounds that have been shown to downregulate bcr/abl protein levels and to render CML cells susceptible to apoptosis or apoptotic stimuli. 21 In this regard, increased activity against bcr/abl þ leukemic cells has been described when STI571 was combined with conventional cytotoxic drugs, 22 arsenic trioxide, 23 geldanamycin 21 or tumor necrosis factor apoptosis-inducing ligand. 24 In the present study, we first investigated the antitumor growth and antiangiogenic effects of different AS-ODNs in K562 cells in vitro and in vivo. The bcr3/abl2 and VEGF AS-ODNs alone can efficiently decrease bcr3/abl2 and VEGF mRNA levels. In combination, these ODNs exerted an additive antiproliferative effect on K562 cells at half of the concentrations at which individual AS-ODNs were only partially effective. Moreover, the combined treatment prominently enhanced the sensitivity of Figure 3 Continued
Enhanced growth suppression of PhK562 cells to the apoptosis induced by etoposide or serum deprivation. Subsequent in vivo experiments further showed that the combined therapy gave rise to an additive action in suppressing the growth of leukemia tumors after four injections. In addition, increased tumor cell apoptosis and decreased tumor microvessel density were observed in the combined therapy group. These findings indicate that although ASO-B3/A2 and ASO-VEGF each can inhibit leukemia tumor growth, their combination results in an additive action in vitro and in vivo.
We then studied the treatment of bcr/abl þ leukemic cell lines with the abl kinase inhibitor STI571 in combination with different AS-ODNs and found that the antiproliferative and proapoptotic activity of low concentration STI571 against bcr/ abl-expressing cells can be significantly enhanced by the addition of AS-ODNs. At high levels of inhibition, combined therapy resulted in an additive effect as seen in MTT assays. This finding was confirmed by analysis of Annexin V in K562 cells, where combination of both different AS-ODNs and low concentration STI571 led to a higher percentage of apoptotic cells compared to the expected effect of either drug alone. In addition, combination of bcr3/abl2 and VEGF AS-ODNs was able to enhance significantly the antiproliferative and proapoptotic activity of STI571. Further in vivo results showed an increase of STI571-induced antitumor effect when the mice bearing K562 xenografted tumors were treated concomitantly by STI571 and the combination of bcr3/abl2 and VEGF AS-ODNs. We used the dose and schedule of STI571 administration on the basis of a previous report showing 50 mg/kg three times a day as the optimal therapy. 25 Our experiments were designed to show whether the combined treatments could obtain the best therapeutic efficacy. Therefore, we selected 70 mg/kg daily therapy as less than optimal therapy to avoid effective dose of STI571 to impair the effect of AS-ODNs.
We have noted that the two AS-ODNs, both being as single agent and as a combination, cannot completely suppress the growth of leukemia tumors. One important reason was that several oncogenes were involved in leukemia development. Blocking bcr/abl and VEGF expressions in K562 cells cannot radically and only partially inhibit the leukemia. Besides, the downside of any transfection approach is the limitation of current vectors to deliver the exogenous message to every tumor cell in vitro and in vivo. The incomplete delivery of the AS-ODNs might be responsible for the lack of a complete anticancer effect. Thus, although we showed leukemia tumor inhibition, we did not observe a complete tumor regression.
In conclusion, our data demonstrate for the first time that targeting both bcr3/abl2 and VEGF may represent an excellent strategy to overcome the resistance to chemotherapeutic agents and ultimately to augment efficacy of chemotherapy in CML. Furthermore, the combination of bcr3/abl2 and VEGF AS-ODNs inhibits additively tumor growth through antioncogene and angiogenesis pathways. These findings are promising and may be helpful to develop a combination-based therapeutic strategy to CML.
